Medicare selects Botox, Trulicity for third round of price negotiations

0
77

Botox and the GLP-1 drug Trulicity are among the latest group of prescription drugs subject to price controls by Medicare.

The Centers for Medicare & Medicaid Services (CMS), the federal agency that runs Medicare, has selected 15 high-cost prescription drugs for government price negotiations. This is the first time the list includes drugs administered in doctors’ offices, not just medications that patients pick up at a pharmacy.

Negotiations with participating drug companies will take place in 2026, and any negotiated or renegotiated prices will go into effect in January 2028. Drug companies can technically choose not to participate in negotiations. However, companies that refuse face a steep federal excise…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here